# DESCRIPTION

## STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

- disclose government rights in invention

## BACKGROUND OF THE INVENTION

- introduce nuclear receptors and TLX

## BRIEF SUMMARY OF THE INVENTION

- provide compounds according to Formula I
- define R groups in Formula I
- provide compounds according to Formula II
- define R groups in Formula II
- describe pharmaceutical composition
- outline methods for promoting neurogenesis and treating diseases

## DETAILED DESCRIPTION OF THE INVENTION

- introduce compounds for TLX modulation

### I. DEFINITIONS

- define general terms
- define "a," "an," and "the"
- define "about" and "around"
- define "comprising," "consisting essentially of," and "consisting of"
- define "alkyl"
- define "alkenyl" and "alkynyl"
- define "alkoxy" and "cycloalkyl"
- define heteroalkyl
- define heteroalkylene
- define halo and halogen
- define haloalkyl
- define aryl
- define heteroaryl
- specify heteroaryl ring positions
- define heterocycloalkyl
- specify heterocycloalkyl ring positions
- specify heterocycloalkyl substitutions
- define heterocycloalkyl
- define hydroxy and hydroxyl
- define amino and alkylamino
- define amido
- define carboxy and oxo
- define sulfonyl
- define pharmaceutically acceptable excipient
- define pharmaceutically acceptable salt
- define neurogenesis and nuclear receptor TLX
- define modulator, agonist, and amount sufficient to promote neurogenesis
- define treat, treatment, and effective amount

### II. TLX MODULATORS

- define compounds of Formula I
- specify R⁹ groups
- provide embodiments of compounds of Formula I
- describe compounds of Formula Ia and Formula Ib
- specify R¹, R², R⁵, R⁶, R⁷, and R⁸ groups
- provide embodiments of compounds of Formula I, Formula Ia, and/or Formula Ib
- describe preparation of compounds using α,β-unsaturated carboxylic acids
- specify R⁴ groups
- provide embodiments of compounds with specific R⁴ groups
- define TLX modulators
- specify R4 in compounds of Formula I, Formula Ia, and/or Formula Ib
- specify R4 in compounds of Formula I, Formula Ia, and/or Formula Ib
- specify R4 in compounds of Formula I, Formula Ia, and/or Formula Ib
- specify R9 in compounds of Formula I, Formula Ia, and/or Formula Ib
- provide embodiments of compounds of Formula I, Formula Ia, and/or Formula Ib
- provide additional embodiments of compounds of Formula I, Formula Ia, and/or Formula Ib
- provide further embodiments of compounds of Formula I, Formula Ia, and/or Formula Ib
- define TLX modulators
- specify compound structures
- provide alternative compound structures
- specify R10 substituents
- provide specific compound embodiments
- define substituents
- specify substituent groups
- provide examples of substituents
- define Rα and Rβ substituents
- define divalent substituents
- define substituents on alkyl group
- define substituents on nitrogen
- define tautomer
- define stereoisomer
- define positional isomers
- describe TLX modulators

### III. PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATION OF TLX MODULATORS

- define pharmaceutical composition
- describe preparation methods
- list oral administration forms
- describe tablet composition
- describe coating techniques
- list topical administration forms
- describe injectable solutions
- describe polymer-based delivery systems
- describe physical delivery techniques
- list additional active agents for combination therapy
- describe biomolecular targets for additional active agents

### IV. METHODS FOR MODULATING TLX AND TREATING CONDITIONS ASSOCIATED WITH NUCLEAR RECEPTOR TLX

- describe TLX modulation methods
- define effective amount of TLX modulator
- describe neurogenesis promotion
- describe disease treatment methods
- list neurological disorders for treatment
- list metabolic disorders for treatment
- list cancers for treatment
- describe dose ranges for TLX modulators
- describe administration intervals
- describe combination therapy with additional active agents

### V. EXAMPLES

- introduce example 1: preparation of singly-substituted piperazine TLX modulators
- describe general procedures for preparing compounds 1-4
- detail preparation of (R)-(4-benzyl-3-methylpiperazin-1-yl)(2-(isopentylam
- detail preparation of (S)-(4-benzyl-3-methylpiperazin-1-yl)(2-(isopentylam
- detail preparation of (R)-(4-benzyl-2-methylpiperazin-1-yl)(2-(isopentylam
- detail preparation of (S)-(4-benzyl-2-methylpiperazin-1-yl)(2-(isopentylam
- introduce example 2: preparation of doubly-substituted piperazine TLX modulators
- detail preparation of 2-((2R,6R)-1-benzyl-6-methyl-4-phenylpiperazin
- describe steps 1-4: N4-Nosylation
- describe steps 5-8: N1-Benzylation, N4-Phenylation
- introduce example 3: preparation of substituted piperazine-2-acetic acids
- describe goals of current studies
- describe target library of 588 compounds
- introduce examples
- describe reductive methylation
- describe acetylation and benzoylation
- describe N-mesylation
- describe benzylation
- describe N-phenylation
- describe Alloc protection
- describe parallel platform compatible procedure
- describe synthetic sequence
- provide NMR and HRMS data for library compounds
- describe compounds
- provide NMR data
- provide HRMS data
- describe compounds
- provide NMR data
- provide HRMS data
- describe compounds
- describe compound 7 {1,4}
- describe compound 7 {2,4}
- describe compound 7 {3,4}
- describe compounds 7 {4,4} to 7 {7,4}
- provide NMR data
- provide HRMS data
- describe compounds 7 {1,5} to 7 {7,5}
- describe compound 7 {1,6}
- provide examples of compounds
- describe NMR spectra of compounds
- describe HRMS spectra of compounds
- provide regioisomers of compounds
- describe NMR spectra of regioisomers
- describe HRMS spectra of regioisomers
- describe examples of piperazine compounds
- provide NMR data for compounds
- describe ALPHA screen assay for TLX-coactivator binding
- present results of ALPHA screen assay
- describe in vivo neurogenesis studies in animals
- outline small molecule oral gavage delivery and CldU injections
- describe immunohistochemistry and confocal microscopy
- present results of in vivo neurogenesis studies
- describe study of TLX agonist activity in human brain organoids
- present results of study in human brain organoids
- describe study of TLX agonists in young mice
- describe study of TLX agonists in 5xFAD mice
- describe study of TLX agonists in old wild-type mice and 5xFAD mice
- describe study of TLX agonist treatment on anxiety behavior
- describe study of TLX agonist treatment on working memory
- present results of studies on anxiety behavior and working memory

### VI. EXEMPLARY EMBODIMENTS

- define compound according to Formula II
- specify embodiment 1
- specify embodiment 2
- specify embodiment 3-10
- specify embodiment 11-13
- specify embodiment 14-15
- define compound formula
- specify substituents for R groups
- provide embodiments of compounds
- specify substituents for R⁴
- provide additional embodiments of compounds
- specify L¹ alkylene
- provide embodiments of compounds with specific R groups
- define pharmaceutical composition
- describe method for promoting neurogenesis
- describe method for treating diseases associated with nuclear receptor TLX

